[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unruptured-intracranial-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unruptured-intracranial-aneurysm":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,73,101,122,149,174,200,225,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100406929","unruptured-cerebral-aneurysm-prediction-of-evolution-100406929",false,"NCT04578808","Unruptured Cerebral Aneurysm: Prediction of Evolution","U-CAN","Inclusion Criteria :\n\n* Subject carrying unruptured, asymptomatic and untreated typical IA of bifurcation, measured on conventional imaging (MRI, CTA or DSA) between 3 and 7 mm of larger diameter.\n* Ability to be followed-up during 3 years decided in consensus multidisciplinary gathering.\n* Age \\> 18 years old.\n\nExclusion Criteria :\n\n* A failure to obtain informed consent\n* Contraindications for undergoing an MRI scan include : (heart pacemaker, a metallic foreign body (metal sliver) in their eye, or aneurysm clip in their brain, severe claustrophobia)\n* Contraindications for a gadolinium contrast medium injection (:eGFR below 30 mL\u002Fmin\u002F1.73 m2, Previous or pre-existing nephrogenic systemic fibrosis, Previous anaphylactic\u002Fanaphylactoid reaction to gadolinium containing contrast agent, Acutely deteriorating renal function, Pregnancy and breast-feeding)\n* A mycotic, fusiform-shaped, or dissecting IA, an IA in relation with an arteriovenous malformation\n* A family history of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrom, fibromuscular dysplasia, or Moya Moya disease\n* Intra-cavernous UIA because the sinus cavernous that is fulfilled with venous blood precluded a reliable assessment of aneurysmal wall enhancement (AWE)","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The protocol has many assets. A prospective nationwide recruitment allows for the inclusion of a large cohort of patients with UIA. It will combine accurate clinical phenotyping and comprehensive imaging with CAWE screening. Besides, it will enable to exploit metadata and to explore new pathophysiological pathways of interest by crossing clinical, genetic, biological, and imaging information.",[24],"Unruptured Intracranial Aneurysm",[26,27,28],"Unruptured Cerebral Aneurysm","Aneurysm Prediction Growth","Unruptured Intracranial aneurysm","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2019-08-19",{"date":37,"type":20},"2031-03-15",{"name":39,"class":40},"Nantes University Hospital","OTHER",29,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100626241","assessment-of-the-clinical-and-economic-impact-of-simsize-a-simulation-software-for-implantable-devices-used-in-the-treatment-of-intracranial-aneurysms-a-prospective-multicenter-study-100626241","NCT07433075","Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.","ESSNAI","Inclusion Criteria:\n\n* Patients aged ≥18 years planned to be treated endovascularly for unruptured intracranial aneurysms.\n* Planned implantable device models is available in the Sim\\&Size simulation database and used following their approved indications.\n* Affiliated with the French social security system.\n* Signed the information and consent form\n\nExclusion Criteria:\n\n* Patients scheduled to undergo endovascular treatment with stents only\n* Patients presenting for treatment of a ruptured aneurysm\n* Patients who have already been treated in the planned deployment area and whose previous treatment presents a potential contact with the new implant.\n* Giant intracranial aneurysm resulting in poor-quality reconstruction in the potential deployment area of the implant during 3DRA acquisition\n* Presence of artifacts on the 3DRA in the potential deployment area of the implant\n* Patients with multiple aneurysms whose treatment is planned during a single procedure and who require separate individual therapeutic strategies. Examples of individual therapeutic strategies excluded from the study: placement of two separate flow diverters without telescopic technique, individual coiling of each aneurysm.\n* Patients for whom pre-planning was performed using Sim\\&Cure software prior to patient randomization.\n* Pregnant or breastfeeding women.\n* Patients under guardianship or conservatorship.\n* Emergency situations.",{"count":50,"type":20},576,"INTERVENTIONAL",[53],"NA","In recent years, endovascular treatment of intracranial aneurysms has seen remarkable growth, now surpassing traditional surgical approaches in terms of frequency of use. However, this transition to endovascular methods is not without its challenges. This type of procedure requires careful selection of the device to be implanted, a decision that is still based on manual two-dimensional measurements. This method is questionable, as it does not always take into account the complexity and specificities of certain aneurysms, where three-dimensional geometry can play a crucial role. As a result, these procedures carry significant risks, such as the need for additional maneuvers to remove or reposition devices, or even deploy another support device, which potentially increases the risk of perioperative complications, the duration of surgery, and the amount of radiation required for imaging. Beyond the impact on the patient, these complications also result in additional costs for the healthcare system, expenses that could likely be avoided if more precise and appropriate tools were used from the outset of the procedure. In this context, optimizing the choice of endovascular devices could have both clinical and economic impacts. Innovative technology such as Sim\\&Size, which supports healthcare professionals in their therapeutic decisions and choice of the appropriate endovascular device, should therefore improve the effectiveness and efficiency of endovascular treatments.\n\nSim\\&Size is a Software as a Medical Device (SaMD) intended to provide a 3D view of the final placement of neurovascular implantable medical devices of the following types: flow diverters, intrasaccular devices, stent devices, and coils. It uses an actual image of the patient produced by 3D rotational angiography. It offers physicians the possibility of simulating the deployment of implantable medical devices in the artery to be treated and predicts the final placement and the extent of apposition of the implant. Sim\\&Size has CE marking and FDA clearance.\n\nThis study is a prospective, randomized, multicenter study whose main objective is to show that the use of Sim\\&Size during the standard endovascular procedure, compared with a standard endovascular procedure without Sim\\&Size, reduces both the actual costs of the hospital stay and the rate of perioperative complications.",[24],[57,58,59,60,61],"endovascular","3D simulation","healthcare costs","intracranial aneurysm","software","2026-05-12",{"date":64,"type":33},"2026-05-13",{"date":66,"type":33},"2026-04-10",{"date":68,"type":20},"2028-06",{"name":70,"class":71},"Sim&Cure","INDUSTRY",6,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100629777","efficacy-and-safety-of-transcutaneous-auricular-vagus-nerve-stimulation-for-postoperative-headache-following-stent-assisted-coiling-of-unruptured-intracranial-aneurysms-100629777","NCT07479082","Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms","IMPACT-HT","Inclusion Criteria:\n\n1. Age 18-80 years\n2. Diagnosed with unruptured intracranial aneurysm confirmed by imaging\n3. Planned to undergo stent-assisted coiling or flow diverter embolization\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. History of SAH, ICH, brain tumor, major trauma, substance abuse, syncope, or seizures\n2. Recurrent\u002Ftraumatic\u002Finfectious\u002Fmyxomatous aneurysms\n3. Primary headache disorders (e.g., migraine, cluster headache, trigeminal neuralgia) not attributed to UIA\n4. Previous vagotomy, migraine surgery, or implanted neurostimulators\n5. Other concurrent electronic\u002Fimplantable devices (e.g., pacemakers, neurostimulators)\n6. Clinically significant hypotension, congenital heart disease, severe arrhythmia, unstable angina, or recent MI\n7. Inability to follow up due to severe psychiatric disorder or refusal\n8. Skin lesions at taVNS placement site\n9. Pregnant or lactating\n10. Participation in other trials","80 Years",{"count":82,"type":20},440,[53],"The goal of this clinical trial is to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in reducing postoperative headache among adults undergoing stent-assisted coiling for unruptured intracranial aneurysms (UIAs). The study will include male and female participants aged 18 to 80 years who are scheduled for endovascular treatment of UIAs with stent-assisted coiling or flow diverter devices.\n\nThe main questions it aims to answer are:\n\n* Can taVNS reduce the incidence of headache within 90 days after stent-assisted embolization of UIAs?\n* Is taVNS safe and well-tolerated in this patient population? Researchers will compare patients receiving active taVNS to those receiving sham stimulation to determine if taVNS leads to fewer postoperative headaches and reduced need for analgesic medications.\n\nParticipants will:\n\n* Wear a taVNS device on the left earlobe (active group) or cymba conchae (sham group) starting 1 day before the procedure\n* Receive 30-minute stimulation sessions, twice daily, until postoperative day 5\n* Undergo follow-up assessments of headache occurrence, pain intensity, analgesic use, and any adverse events through day 90 after the procedure",[24,86,87],"Headache","Vagus Nerve Stimulations",[24,89,90],"Postoperative Headache","Vagus Nerve Stimulation","2026-03-13",{"date":93,"type":33},"2026-03-18",{"date":95,"type":33},"2025-09-30",{"date":97,"type":20},"2027-07",{"name":99,"class":40},"Beijing Tiantan Hospital",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":51,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":100},"100599851","indobufen-versus-aspirin-in-endovascular-unruptured-intracranial-aneurysms-treatment-input-100599851","NCT07089862","INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)","Indobufen Versus Aspirin in Endovascular Unruptured Intracranial Aneurysms Treatment","Inclusion Criteria:\n\n1. Age 18-75 years (male or female);\n2. Radiologically confirmed saccular intracranial aneurysm (by specialist assessment);\n3. Scheduled for endovascular embolization (including: coil embolization with stent assistance or flow diversion);\n4. Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Concomitant vascular malformations, tumors, abscesses or other cerebral diseases such as multiple sclerosis;\n2. Major surgery within 30 days prior to enrollment including fracture surgery or hip replacement;\n3. History of ischemic stroke, ischemic heart disease or hemorrhagic disorders including intracranial hemorrhage, gastrointestinal bleeding, fundus hemorrhage or unexplained bleeding within the past 6 months;\n4. Planned elective surgery within 3 months after the procedure;\n5. Any hematologic disorders or inherited coagulation abnormalities;\n6. Severe renal or hepatic dysfunction;\n7. History of hemostatic disorders, systemic bleeding, thrombocytopenia or neutropenia;\n8. History of symptomatic non-traumatic intracranial hemorrhage or cerebral amyloid angiopathy;\n9. Severe cardiopulmonary diseases considered by investigators to be unsuitable for the study;\n10. Women of childbearing potential with negative pregnancy test but refusing contraceptive measures, or those who are pregnant or lactating;\n11. Current participation in other investigational drug or device trials.\n\nWithdrawal Criteria:\n\n1. Receiving aneurysm treatment other than coil embolization with stent assistance or flow diversion;\n2. Occurrence of endpoint events during stent-assisted aneurysm embolization procedure (as adjudicated by the Clinical Events Committee), including procedure-related hemorrhagic events (aneurysm rupture, parent artery rupture, subarachnoid hemorrhage, acute ipsilateral intracerebral hemorrhage, and acute ipsilateral subdural\u002Fepidural hematoma) or ischemic events (acute large vessel occlusion, in-stent thrombosis, and diffuse ipsilateral vascular infarction caused by plaque dislodgement);\n3. Device-related quality issues during stent-assisted embolization, including stent problems (stent fracture, failure to deploy properly, incomplete expansion due to product defect) and coil problems (premature detachment before intentional deployment, coil unraveling, and failure to detach);\n4. Postoperative life expectancy \\\u003C3 months;\n5. Inability to complete 5-day premedication due to emergency surgery or other reasons;\n6. Intolerance to oral antiplatelet therapy due to allergy or other contraindications.","75 Years",{"count":110,"type":20},2500,[53],"This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms.\n\nUsing a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.\n\nAn independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.",[24,114],"Indobufen",{"date":116,"type":33},"2026-03-16",{"date":118,"type":33},"2025-08-31",{"date":120,"type":20},"2026-12-31",{"name":99,"class":40},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":132,"studyType":21,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":100},"100626771","investigation-of-protein-heterogeneity-in-extracellular-vesicles-derived-from-different-human-blood-circulatory-regions-100626771","NCT07439965","Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions","DBCR-EV-p","Inclusion Criteria:\n\n* 1\\. Aged between 18 and 60 years, regardless of gender; 2. Diagnosed with intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have CT imaging evidence of hemorrhage, and blood collection must occur within 3 days of symptom onset; 4. Scheduled to undergo neurointerventional surgery for intracranial aneurysm under general anesthesia, with the procedure starting between 8:00 AM and 12:00 PM; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with a pre-onset (in hemorrhagic cases) or preoperative (in non-hemorrhagic cases) Modified Rankin Scale (MRS) score ≥ 2; 2. Presence of other neurological disorders such as Parkinson's disease, Alzheimer's disease, cerebral infarction, brain tumors, epilepsy, etc.; 3. Presence of other systemic diseases such as diabetes, coronary artery disease, cancer, infections, hematological diseases, or severe metabolic disorders that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT \\> 3 times the upper limit of normal; creatinine \\> 225 μmol\u002FL); 5. Patients who cannot tolerate anesthesia, anticoagulant therapy, or who have coagulation disorders; 6. History of severe allergic reactions to contrast agents; 7. Pregnant women; 8. Patients participating in other clinical trials who have not yet completed follow-up.","60 Years",{"count":131,"type":20},120,"120 Days","The goal of this observational study is to learn about the protein heterogeneity in extracellular vesicles (EVs) derived from different human blood circulatory regions of patients with ruptured or unruptured intracranial aneurysms. The main objectives are:\n\nReveal the proteomic heterogeneity of EVs in different blood circulatory regions of the human body。 Reveal the proteomic differences of EVs in cerebral feeding arteries and draining veins between patients with aneurysmal subarachnoid hemorrhage and those without hemorrhage.\n\nExplore EV-derived protein biomarkers that reflect the diagnosis and prognosis of subarachnoid hemorrhage",[135,24],"Subarachnoid Aneurysm Hemorrhage",[137,138,139,60],"extracellular vesicles","blood","subarachnoid hemorrhage","2026-02-23",{"date":142,"type":33},"2026-02-27",{"date":144,"type":33},"2025-07-29",{"date":146,"type":20},"2026-06",{"name":148,"class":40},"The First Hospital of Jilin University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":156,"targetDuration":4,"studyType":51,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":100},"100612856","lumens-1-canada-early-feasibility-study-clinical-investigation-plan-100612856","NCT07259018","LUMENS-1 Canada Early Feasibility Study Clinical Investigation Plan","A Single-arm, Open Label, Single-center Early Feasibility Study of the LuSeed Aneurysm Embolization System in Individuals With Unruptured Intracranial Aneurysms.","Inclusion Criteria:\n\n1. Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n2. Age 18-80 years at screening\n3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n4. The IA must have had the following characteristics:\n\n   * IA located in bifurcation in the anterior or posterior circulation\n   * IA dimensions appropriate for treatment with LuSeed- Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for\n\n   Use (IFU) and as follows:\n   * IA Width: 2.5-5.5\\[mm\\]\n   * IA Neck: 2.0-5.0\\[mm\\]\n   * IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration • The AI must meet the definition of a \"wide-neck\" aneurysm.\n5. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements\n6. Patient able to give their informed consent can be included in this study.\n\nExclusion Criteria:\n\n1. Ruptured intracranial aneurysm\n2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n3. Contraindication for arterial access\n4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n6. Intracranial aneurysm minimum height less than 4.0 mm\n7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n8. Stenosis of the target IA's parent vessel \\>50%\n9. Known allergy to platinum, nickel, or titanium\n10. Known allergy to contrast agents\n11. Absolute contraindication to anticoagulation or antiplatelet therapy\n12. Anticoagulation medications such as warfarin that cannot be discontinued\n13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n15. Cerebral embolism, stroke, or TIA in past 6 months\n16. Myocardial infarction in the past 6 months\n17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n21. Patient had a life expectancy of less than 12 months.\n22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.",{"count":5,"type":20},[53],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a single-arm, open-label, single-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 10 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled in a Canadian site.",[160,161,24,162,163],"Aneurysm Cerebral","Bifurcation","Saccular Aneurysm","Brain Aneurysm","NOT_YET_RECRUITING","2025-12-02",{"date":167,"type":33},"2025-12-09",{"date":169,"type":20},"2025-12",{"date":171,"type":20},"2028-05",{"name":173,"class":71},"LuSeed Vascular LTD.",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":181,"targetDuration":4,"studyType":51,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":72},"100574598","lumens-1-eu-efs-cip-100574598","NCT06761365","LUMENS-1 EU EFS CIP","A SINGLE-ARM, OPEN LABEL, MULTI-CENTER EARLY FEASIBILITY STUDY OF THE LUSEED ANEURYSM EMBOLIZATION SYSTEM IN INDIVIDUALS WITH UPRUPTURED INTRACRANIAL ANEURYSMS","Inclusion Criteria:\n\n* Patients indicated for treatment of unruptured intracranial aneurysms (IA) according to AHA \u002F ASA Guidelines.\n\n  1. Age 18-80 years at screening\n  2. Patients who are suitable for non-emergency endovascular embolization of saccular IAs\n  3. The IA must have had the following characteristics:\n* IA located in the anterior or posterior circulation\n* IA dimensions appropriate for treatment with\n\nLuSeed-Vascular Embolization Device per implant size selection guidelines as outlined in the Instructions for Use (IFU) and as follows:\n\n* IA Width: 2.5-5.5\\[mm\\]\n* IA Neck: 2.0-5.0\\[mm\\]\n* IA Height: min 4.0 \\[mm\\]- device short configuration, min 5.0 \\[mm\\]-device long configuration 4. Patient is willing and able to participate in the study for the duration of the study follow-up and can comply with study requirements Exclusion Criteria: 5. Patient able to give their informed consent can be included in this study. Exclusion Criteria\n\n  1. Ruptured intracranial aneurysm\n  2. Patient anatomy or physiology considered unsuitable for endovascular treatment as determined by imaging Core Lab\n  3. Contraindication for arterial access\n  4. Intracranial aneurysm neck diameter less than 2mm or greater than 5 mm\n  5. Intracranial aneurysm sac diameter less than 2.5mm or greater than 5.5mm\n  6. Intracarnial aneurysm minimum hight less than 4.0 mm\n  7. Target Intracranial aneurysm contains other devices\u002Fimplants (e.g., coils)\n  8. Stenosis of the target IA's parent vessel \\>50%\n  9. Known allergy to platinum, nickel, or titanium\n  10. Known allergy to contrast agents\n  11. Absolute contraindication to anticoagulation or antiplatelet therapy\n  12. Anticoagulation medications such as warfarin that cannot be discontinued\n  13. Pregnant, breastfeeding or planning pregnancy within next 12 months\n  14. Acute or chronic renal failure (stage III or IV by VARC-3 criteria)\n  15. Cerebral embolism, stroke, or TIA in past 6 months\n  16. Myocardial infarction in the past 6 months\n  17. Any other medical issue within the brain that would preclude device implantation (such as brain surgery, radiation in the target area of intervention from an external beam source, acute traumatic craniocerebral injury, etc.)\n  18. Patient had any circulatory, neurovascular, cardiovascular, or neurologic conditions that resulted in unstable neurological symptoms at screening.\n  19. Patient had physical, neurologic or psychiatric conditions which precluded his\u002Fher ability to comply with all aspects of the screening, evaluation, treatment, and the postprocedure follow-up schedule.\n  20. Other medical conditions that cause an inability to comply with study requirements and\u002For that could increase the risk of neurovascular procedures (e.g., extreme frailty, liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)\n  21. Patient had a life expectancy of less than 12 months .\n  22. Current participation in another study with investigational devices or drugs that would confound the effect of the study outcomes.",{"count":182,"type":20},30,[53],"The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a prospective, single-arm, open-label, multi-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 30 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled across a maximum of 10 medical centers in the EU.",[160,161,24,162,163],[161,187,188,189,190,191],"Embolization","Flow Diverter","Intrasaccular Device","Cerebral Aneurysm","Unruptured","2025-11-21",{"date":194,"type":33},"2025-11-26",{"date":196,"type":33},"2024-10-07",{"date":198,"type":20},"2027-06",{"name":173,"class":71},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":208,"targetDuration":4,"studyType":51,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100579580","chronic-remote-ischemic-conditioning-in-small-infarctions-associated-with-stent-assisted-coiling-of-unruptured-intracranial-aneurysms-100579580","NCT06826144","Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms","Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms: a Single-center Randomized Controlled Trial.","CRISIS","Inclusion Criteria:\n\n* 1\\) Age 18-80; 2) Unruptured aneurysm with surgical indications; 3) Stent assisted aneurysm embolization; 4) Patients were willing to receive ischemic adaptation therapy.\n\nExclusion Criteria:\n\n* 1\\) Age \\\u003C 18 years old; 2) Complicated with cerebrovascular malformations, moyamoya disease and other hemorrhagic cerebrovascular diseases or history; 3) pregnancy; 4) History of acute myocardial infarction within 1 month; 5) Peripheral vascular disease or peripheral neuropathy of the upper limb; 6) Upper limb vascular and soft tissue injury, or combined with limb deformity; 7) Severe subclavian artery stenosis or occlusion; 8) Poor blood pressure control, upper extremity basal systolic pressure ≥200mmHg; 9) Chronic kidney disease.",{"count":209,"type":20},84,[53],"1. Disease Description Stent-assisted coiling has become an effective treatment modality for intracranial aneurysms. With continuous advancements in periprocedural antiplatelet regimens, the incidence of symptomatic thromboembolic events has significantly decreased. However, the rate of procedure-related microembolic infarctions, which are characterized by punctate hyperintense signals on DWI, remains high (10%-76.5%). The underlying causes of these microembolic infarctions remain controversial and may be associated with factors such as different stent types, sheath types, antiplatelet regimens, intraoperative adverse events (e.g., vascular dissection or spasm), patient age, and procedure duration. While most patients with microembolic infarctions exhibit no overt clinical symptoms, the presence of these infarctions reflects underlying tissue damage, posing potential risks that cannot be ignored. Furthermore, their occurrence highlights insufficient preoperative preparation or intraoperative technical issues, which may increase the likelihood of symptomatic embolism. Therefore, investigating the causes of microembolic infarctions and exploring preventive strategies is of great clinical significance.\n2. Intervention Description Remote ischemic conditioning (RIC) involves inducing temporary ischemia in distal vessels to protect target vessels from ischemic and reperfusion injuries. RIC can be performed before, during, or after ischemic events and is widely used in the context of coronary artery ischemia. Some studies have shown that RIC can mitigate ischemia-related injuries in the myocardium, kidneys, and lower limbs following cardiovascular surgeries. Previous research has also demonstrated the neuroprotective effects of RIC in ischemia-reperfusion injuries of the nervous system. For instance, RIC significantly improves outcomes in cerebral small vessel disease (CSVD)-related acute stroke events and ameliorates cognitive impairments associated with CSVD. Moreover, the safety and efficacy of RIC have been validated in other conditions or procedures, such as aneurysmal subarachnoid hemorrhage (aSAH), intracranial atherosclerotic stenosis, and carotid artery stenting.\n3. Research Hypothesis Current clinical studies on RIC have primarily focused on acute ischemic stroke (including large artery atherosclerosis and CSVD), spontaneous intracerebral hemorrhage, and subarachnoid hemorrhage. The Remote Ischemic Conditioning for Acute Stroke Trial (RESIST) indicated that RIC effectively improves outcomes in acute strokes related to CSVD, including reducing white matter hyperintensities, infarct volume, and modified Rankin Scale (mRS) scores. A clinical study conducted at the Mayo Clinic demonstrated the safety of remote ischemic preconditioning (RIPC) during intracranial aneurysm coiling. Our center's previous study on \"Tirofiban and Procedure-Related Microemboli in Stent-Assisted Aneurysm Coiling\" revealed that the incidence of procedure-related microembolic infarctions was 61.1% in the non-tirofiban group and 19.4% in the tirofiban-treated group. However, there is currently a lack of research on the use of RIC for procedure-related microembolic infarctions in stent-assisted aneurysm coiling.\n\nThis study aims to explore the efficacy of ischemic conditioning treatment, performed preoperatively and postoperatively, in reducing procedure-related microembolic infarctions during standard stent-assisted aneurysm coiling. The primary outcomes include the incidence of acute microembolic infarctions postoperatively and the incidence of symptomatic microembolic infarctions at one month following RIC.",[24,213],"Infarction Cerebral",[215],"remote ischemic conditioning","2025-02-10",{"date":218,"type":33},"2025-02-13",{"date":220,"type":20},"2025-02-20",{"date":222,"type":20},"2026-06-01",{"name":224,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":51,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":100},"100570502","patients-with-unruptured-intracranial-aneurysms-evaluation-of-the-benefits-of-allied-health-follow-up-in-a-randomized-controlled-trial-100570502","NCT06708078","Patients with Unruptured IntraCranial ANeurysms: Evaluation of the Benefits of Allied Health FollOw-uP in a RandomizEd Controlled Trial","CANHOPE","Inclusion Criteria:\n\n* Patient with newly diagnosed (\\\u003C9 months) untreated Intracranial Aneurysm\n* Patient with untreated Intracranial Aneurysm monitored by imaging\n* Patient over 18\n* Patient agreeing to participate in the study and having signed the consent form\n\nExclusion Criteria:\n\n* Patient with a history of ruptured Intracranial Aneurysm\n* Patient under guardianship or curatorship\n* Patient diagnosed with a syndrome known to cause Intracranial Aneurysm :\n\n  * Marfan syndrome\n  * AOS (Aneurysm Osteoarthritis Syndrome) with SMAD 3 mutations\n  * Type II and IV Elhers Danlos syndrome\n  * Autosomal dominant polycystic fibrosis\n  * Moya-Moya syndrome\n* Patient with:\n\n  * Dissecting or fusiform Intracranial Aneurysm\n  * Intracranial Aneurysm associated with an arteriovenous malformation\n  * Blister-like Intracranial Aneurysm\n  * Mycotic Intracranial Aneurysm",{"count":233,"type":20},340,[53],"The CANHOPE study falls within the scope of research on patients' experiences and the improvement of their management through interventions meeting their needs.\n\nThe study protocol assesses a support program for patients with untreated intracranial aneurysms (ICAs), for whom several sources of data converge in describing inadequacies in patients' care pathway and a deleterious impact on their health.\n\nThe initial questioning is based on the practice of caregivers, who are witnesses of patients' feelings during ICA follow-up and are sometimes unable to support them due to a lack of knowledge about the impact of the disease and an organization that does not provide any space dedicated to their support.\n\nThe study topic described below explains the medical context of ICA, and the data available in the literature on the impact of this condition on patients' lives. These data are complemented by the results of a qualitative study recently conducted in Nantes University Hospital in 10 subjects who participated in two focus groups. The discussions have revealed many areas of tension related to the management of uncertainty: \"questions arise after the consultation\"; \"there should be an ALLO INFO ANEURYSM number\"; \"if it ruptures, it's over, that's what I've understood\"; \"I fall asleep every night thinking it might be the last time\". The need for specific support, particularly during the first year, appears to be obvious.\n\nBased on these experiences, it has been hypothesized that an allied health follow-up of patients managed by simple monitoring, focused on the management of uncertainty, during the first year following the announcement, could reduce anxiety and improve patients' quality of life.\n\nInspired by participants' experiences and guided by the uncertainty in illness theory, the study is focused on proposing an allied health management organized around items known to sustain patients' hope.\n\nThe aim of the CANHOPE study is therefore to assess the CANHOPE program, in order to provide clinicians and decision-makers with the data they need to support the implementation of this program in referral centers for ICA follow-up. This study will be conducted in two parallel parts: 1\u002F a multicenter, cluster, randomized, controlled trial and 2\u002F a comprehensive qualitative study.",[24],[238,239,240,241],"Unruptured intracranial Aneurysm","Neuroradiology","Patient's care pathway","Quality of life","2024-11-25",{"date":244,"type":33},"2024-11-27",{"date":246,"type":33},"2023-11-07",{"date":248,"type":20},"2028-05-06",{"name":39,"class":40},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":51,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":100},"100570300","mri-analysis-in-the-growth-of-cerebral-aneurysms-100570300","NCT06705452","MRI Analysis in the Growth of Cerebral Aneurysms","4D-MRI Morphological Study of Local Growth in Cerebral Aneurysms","EPICAVC","inclusion criteria:\n\n* Patients with one or more unruptured intracranial aneurysms followed up at the participating center. Patients may have other ruptured and\u002For treated aneurysms\n* Patient older than 18 years\n* Patient consenting to participate to the study\n* Patient enrolled in the national healthcare insurance program\n\nexclusion criteria:\n\n* Patients who have already received surgical or endovascular treatment for all their aneurysm(s), or who are due to receive such treatment in less than 2 months.\n* Patients with only ruptured aneurysm(s)\n* Patients with arteriovenous malformations (treated or untreated)\n* Patients with a contraindication to MRI\n* Patients with an allergy to one of the contrast agents (Iodixanol, Gadoteric acid)\n* Pregnant or breast-feeding patients\n* Patients protected by law.",{"count":259,"type":20},281,[53],"An intracranial aneurysm is defined as a localized dilatation of the cerebral arteries, which can potentially lead to rupture and subsequent hemorrhagic stroke. The mechanisms by which aneurysms develop and grow remain unknown. The objective of this project is to utilize MRI, a routine non-invasive examination for detecting and following up aneurysms, to identify visually and quantitatively an aneurysm growth and relevant biomarkers that can predict the risk of aneurysm development.",[24],[264,28,190,265,266,267],"Aneurysm Growth","Vascular Diseases","Intracranial Arterial Diseases","Intracranial Aneurysm","2024-11-22",{"date":270,"type":33},"2024-11-26",{"date":272,"type":20},"2025-01-01",{"date":274,"type":20},"2032-01-01",{"name":276,"class":40},"CHU de Reims"]